EFFECTS OF EARLY ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN A PIG MODEL OF MYOCARDIAL-ISCHEMIA AND REPERFUSION

被引:13
作者
VANWIJNGAARDEN, J
TOBE, TJM
WEERSINK, EGL
BEL, KJ
DEGRAEFF, PA
DELANGEN, CDJ
VANGILST, WH
WESSELING, H
机构
[1] Department of Pharmacology, Clinical Pharmacology, University of Groningen, Groningen
关键词
ANGIOTENSIN-CONVERTING ENZYME INHIBITION; MYOCARDIAL ISCHEMIA; REPERFUSION; PIG; NEUROHUMORAL MODULATION; PERINDOPRIL;
D O I
10.1097/00005344-199203000-00017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a blind, randomized study, the effects of perindopril, a nonsulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor, were compared with those of placebo in a closed-chest pig model of myocardial infraction. In anesthetized pigs, my ocardinal ischemia and reperfusion were induced by inflation and deflation of a catheter balloon in the left anterior descending coronary artery (LAD), respectively. Thirty minutes after induction of ischemia and 15 min before reperfusion, a bolus injection of 0.06 mg/kg perindoprilat (n = 12), the active compound of peridopril, or placebo (n = 12) was administered in the pulmonary artery of these animals. After the acute phase of myocardial infarction, treatment with 12 mg/day perindopril or placebo was continued orally for 2 weeks. During the entire treatment period, 7 of 12 animals died in the placebo group versus 2 of 12 animals in the perindopril group (Fisher's exact test p < 0.04). This beneficial effect of perindopril on mortality could not be attributed to salvage of myocardial tissue because the increases in creatine phosphokinase and coronary venous purine levels were similar in perindopril- and placebo-treated animals. Neither were there any significant between-treatment differences in the hemodynamic and (neuro)humoral parameters during the acute phase of myocardial infarction. The difference in mortality was observed within 24 h after myocardial infarction. Prevention of acute pump failure and, especially, life-threatening ventricular arrhythmias may explain this improvement in survival by perindopril. Retrospectively, logistic regression analysis showed that, irrespective of treatment, survival was inversely correlated to plasma renin activity (PRA) before induction of ischemia (r = -0.33; p < 0.02). High initial PRA levels most likely reflected increased angiotensin II (ANGII) activity, which might have been beneficially influenced by perindopril. In addition, during the acute phase of myocardial infarction, prostaglandin E2 (PGE2) levels were significantly higher in animals that survived than in animals that died, but to establish the role of these humoral parameters to morality in myocardial infarction definitively prospective studies are needed.
引用
收藏
页码:408 / 416
页数:9
相关论文
共 28 条
[1]   ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION [J].
ALDERMAN, MH ;
MADHAVAN, S ;
OOI, WL ;
COHEN, H ;
SEALEY, JE ;
LARAGH, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (16) :1098-1104
[2]   DIFFERENTIATION OF ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS BY THEIR SELECTIVE-INHIBITION OF ACE IN PHYSIOLOGICALLY IMPORTANT TARGET ORGANS [J].
CUSHMAN, DW ;
WANG, FL ;
FUNG, WC ;
HARVEY, CM ;
DEFORREST, JM .
AMERICAN JOURNAL OF HYPERTENSION, 1989, 2 (04) :294-306
[3]  
deGraeff P A, 1988, Am J Med, V84, P67, DOI 10.1016/0002-9343(88)90207-0
[4]   CONCENTRATION-DEPENDENT PROTECTION BY CAPTOPRIL AGAINST MYOCARDIAL DAMAGE DURING ISCHEMIA AND REPERFUSION IN A CLOSED CHEST PIG MODEL [J].
DEGRAEFF, PA ;
VANGILST, WH ;
BEL, K ;
DELANGEN, CDJ ;
KINGMA, JH ;
WESSELING, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1987, 9 :S37-S42
[5]   LIMITATION OF EXPERIMENTAL INFARCT SIZE BY AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR [J].
ERTL, G ;
KLONER, RA ;
ALEXANDER, RW ;
BRAUNWALD, E .
CIRCULATION, 1982, 65 (01) :40-48
[6]   EFFECTS OF ENDOGENOUSLY PRODUCED LEUKOTRIENES, THROMBOXANE, AND PROSTAGLANDINS ON CORONARY VASCULAR-RESISTANCE IN RABBIT MYOCARDIAL-INFARCTION [J].
EVERS, AS ;
MURPHREE, S ;
SAFFITZ, JE ;
JAKSCHIK, BA ;
NEEDLEMAN, P .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (03) :992-999
[8]  
GROVER GJ, 1991, J PHARMACOL EXP THER, V257, P919
[9]  
HOCK CE, 1985, AM HEART J, V280, P181
[10]  
KINGMA JH, 1989, NEW FRONTIERS CARDIO, P277